Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2000 Apr;105(7):847-51.
doi: 10.1172/JCI9762.

Replication-selective adenoviruses as oncolytic agents

C Heise  1 , D H Kirn
Affiliations
Review

Replication-selective adenoviruses as oncolytic agents

C Heise et al. J Clin Invest. 2000 Apr.
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
Structure of human adenovirus, indicating the arrangement of capsid proteins. Fiber and penton recognize cellular receptors that mediate endocytosis of the virus.
Figure 2
Figure 2
Selective killing of cancer cells with a replication-selective agent. Viral agents can be engineered to replicate in and to kill tumor cells specifically, leaving healthy cells unharmed. Several strategies are available for designing such agents.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Whyte P, Williamson N, Harlow E. Cellular targets for transformation by the adenovirus E1A proteins. Cell. 1989;56:67–75. - PubMed
    1. Barker DD, Berk AJ. Adenovirus proteins from both E1B reading frames are required for transformation of rodent cells by viral infection and DNA transfection. Virology. 1987;156:107–121. - PubMed
    1. Gomez-Manzano C, et al. Adenovirus-mediated transfer of the p53 gene produces rapid and generalized death of human glioma cells via apoptosis. Cancer Res. 1996;56:694–699. - PubMed
    1. Roth J, Cristiano RJ. Gene therapy for cancer: what have we done and where are we going? J Natl Cancer Inst. 1997;89:21–39. - PubMed
    1. Merritt J, et al. Clinical phase I experience with INGN 201 (Ad-p53) in non-small cell lung cancer and head and neck cancer. Cancer Gene Ther. 1997;4:S12. (Abst. )